Skip to main content
. 2014 Mar 10;9(3):e91775. doi: 10.1371/journal.pone.0091775

Figure 5. The effects of LPM570065, desvenlafaxine and vehicle on the extracellular DA levels after acute administration.

Figure 5

The effects of LPM570065 (black line), desvenlafaxine (red line) and vehicle (blue line) on the extracellular DA levels in the rat striatum after acute administration using different administration routes are indicated as follows: (A) for oral solution, (B) for oral suspension and (C) for intravenous solution. LPM570065 and desvenlafaxine (0.06 mmol·kg−1 for oral solution; 0.06 mmol·kg−1 for oral suspension; 0.04 mmol·kg−1 for intravenous solution) or the appropriate vehicle was administered at time 0 min. Data are presented as the mean±SD, n = 7–8; ***p<0.001 LPM570065 vs. relative vehicle; two-way ANOVA with repeated measures. (D) The overall effects on the extracellular DA levels in the rat striatum following treatment with LPM570065, desvenlafaxine or vehicle using different administration routes (blue column: oral solution; black column: oral suspension; red column: intravenous solution). The columns represent the AUC0–160 min values calculated as the differences in relative changes in the extracellular DA levels over a 2.7-h period between the drug-treated and relative vehicle-treated groups. Data are presented as the mean±SD, n = 7–8; ***p<0.001, *p<0.05 LPM570065 vs. relative vehicle; one-way ANOVA.